Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study
Top Cited Papers
- 1 March 2002
- journal article
- clinical trial
- Published by Elsevier in The Lancet
- Vol. 359 (9309) , 824-830
- https://doi.org/10.1016/s0140-6736(02)07952-7
Abstract
No abstract availableKeywords
Funding Information
- Diabetesforeningen
- Sundhed og Sygdom, Det Frie Forskningsråd
- Novo Nordisk Fonden
This publication has 29 references indexed in Scilit:
- Effect of Nutrient Ingestion on Glucagon-Like Peptide 1 (7-36 Amide) Secretion in Human Type 1 and Type 2 DiabetesHormone and Metabolic Research, 2000
- Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studiesInternational Journal of Obesity, 2000
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998
- Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.Journal of Clinical Investigation, 1997
- Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitusEuropean Journal of Clinical Investigation, 1997
- Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in MenDiabetes Care, 1994
- Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patientsDiabetologia, 1993
- Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trialDiabetes Care, 1993
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANPublished by Elsevier ,1987
- Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1984